Form 4: BioAffinity Technologies Director Jamie Platt Reports Share Acquisition and Disposal

Director Jamie Platt reports acquisition of 33,784 shares and disposal of shares in bioAffinity Technologies, Inc.

Summary

• On July 1, 2024, Jamie Platt, a director of bioAffinity Technologies, Inc., reported acquiring 33,784 shares of common stock.
• These shares were acquired at a price of $0.
• Platt also disposed of 54,748 shares.
• Following these transactions, Platt beneficially owns 54,748 shares of common stock.
• The acquisition of 33,784 shares represents a grant of restricted shares that will vest pro rata on a monthly basis over 12 months, starting August 1, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The document reports transactions without expressing any positive or negative outlook. The disposal of shares is balanced by the acquisition of restricted shares.

Positives

• The grant of restricted shares to a director could be seen as a positive sign, aligning the director's interests with the company's long-term performance.

Negatives

• The disposal of 54,748 shares by the director could be interpreted negatively by investors.

Risks

• The disposal of a significant number of shares by a director could create uncertainty among investors regarding the company's prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the restricted shares suggests a commitment to the company's future over the next 12 months.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders. It provides transparency into the transactions of company directors and their holdings in the company.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.

Key Dates

Keywords

bioAffinity Technologies, Jamie Platt, Form 4, share acquisition, share disposal, director, beneficial ownership, restricted shares, BIAF